GSK’s Responds To FDA On Cervarix, Will Augment BLA With More Efficacy Data
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.
Firm will send final study data on the cervical cancer vaccine to FDA in the first half of 2009, and approval could come six months later.